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EDITORIAL
The role of the clinical editor
A separate Clinical Section in the British Journal of Cancer
was started by Dr Michael Moore during his time as Editor
and grew substantially under his careful supervision. Michael
felt that there were particular requirements in the editing
process for clinical papers that differed from those for labor-
atory experimental science, his own discipline. He felt that
the Clinical Section should have a clinically-qualified editor
and this change was instituted in January 1988. Are there
really any special requirements in the clinical editorial pro-
cess?
After 3 years' experience it is possible to conclude that
there are some differences in the approach to editing a
clinical section. Clearly the content of the papers differs
considerably from that of experimental laboratory science
papers and a working knowledge of clinical practice, clinical
research and clinical trials methodology is a prerequisite for
critically evaluating most papers in a clinical section. Clinic-
ians tend to have some knowledge and experience of epider-
miology and this is also an asset. However, we remain mostly
dependent upon our reviewers for their expert knowledge
about a particular paper and it would be a lucky Clinical
Editor indeed who found that he or she understood com-
pletely all the clinical papers in any issue.
In this editorial we are going to focus particularly upon the
necessary differences in the editorial process that result from
the rather different audience reached by a clinical section.
Papers on laboratory science are read mainly by experiment-
alists. Their fields of interest may be quite different, but the
practice of science is a common theme for them all. In the
Clinical Section, many of the readers will be actively engaged
in research, but equally many of the clinicians reading the
British Journal of Cancer may no longer be involved in
research and may be seeking conclusions from ongoing
research which are relevant to their daily clinical practice.
For instance, are clinical trials showing significant advances
in particular tumour types? Has adjuvant treatment for a
particular cancer yet been shown to be worthwhile? These
readers may take away from the Journal a different message
from the clinical scientist who may be most interested in
planning his own next study. We do not feel that it is
appropriate to be too concerned about this difference in the
audience when considering the primary publication ofclinical
scientific efforts. Papers that are submitted are reviewed in
principle in much the same way. The Clinical Editor has a
slightly different style tending to prefer individual response
letters to authors, but this has little influence on the decision to
accept or reject manuscripts and the acceptance rate for the
Clinical Section is very similar to that for the Experimental
Section. For epidemiological manuscripts three reviews are
the norm, whereas for clinical manuscripts two reviewers are
used more frequently simply reflecting the particular experi-
ence of the present incumbent of the Clinical Editorship.
In a direct effort to make the Journal more interesting,
accessible and useful for readers who are not themselves
primarily involved in clinical research, we introduced
editorials which seek either to comment on current papers or
to present an overview or point of view on current areas of
research. The aim is to establish a steady programme of
editorials, between two and four each month, that will add
interest for the non-specialist and a measure of critical app-
raisal of individual papers. So far this approach seems to
have been warmly received by most readers. In future it will
be our policy also to use this approach both in epidemiology
and laboratory science, perhaps to increase the amount of information that the Journal can transfer across the boun-
daries between the different disciplines.
A few areas are perhaps of particular importance for the
clinical literature and less important for the experimental
laboratory papers. The ethics of human research are clearly ofprincipal concern to the clinician who will have immediate
patient contact and responsibility. Laboratory scientists will
be naturally concerned that the samples upon which they work when they carry out clinically-based research are taken
only after careful consideration of the ethical issues, but the
clinical scientist has to consider ethical issues day by day. In
the British Journal of Cancer, we principally rely upon acknowledgement by authors that a study has been carried
out subject to the approval of the Institutional Ethical
Review Boards of the hospitals involved. Occasionally confir-
mation that this was the case has been sought from authors.
However, no paper has been rejected in the last 3 years on
purely ethical grounds although we would reserve the right to
do so if, after very careful consideration and discussion with
colleagues, it was felt that a paper has been approved by an
Institutional Ethical Review bQdy, but was nevertheless at
variance with accepted medical ethics.
The publication of negative results may be particularly important for the clinician. Not only may it allow modifi-
cation of treatment policies and in particular the rejection of
ineffective therapies, but it also avoids unnecesary repetition of research. For this reason it is editorial policy to publish
appropriate negative observations in the form ofcomparative clinical trials or negative observations regarding the effect-
iveness of treatments. We try to ensure an even-handed
policy between positive and negative observations although
even such an editorial policy cannot correct for more rapid and more certain submission of positive results for publica-
tion. This policy does not correct for the inevitable publica- tion bias in the literature in favour of positive results, but
can only serve to minimise it.
There are perhaps special considerations within the Clin-
ical Section which relate to the choice of methodology. Most
laboratory scientists would be surprised by the suggestion that they might publish uflcontrolled experiments. In clinical
science, uncontrolled experiments are common and show no
signs of dying out. This is not to be totally condemned
because important observations are made by clinical descrip- tion of cases, series or treatments. Toxicity can often be
characterised without controls although subtle degrees of
toxicity are hard to interpret in the absence of some idea of
the incidence in control populations. Efficacy can be demon-
strated, but not measured accurately in uncontrolled studies.
Historical comparisons of response rates may be moderately informative if allowance is made for patient selection.
Historical comparisons of remission duration or survival are
notoriously misleading and rarely helpful. Should it therefore
be the policy of a Clinical Editor to automatically reject all
papers in which remission duration and survival are describ-
ed without concurrent randomised controls? At present we
believe this is not possible, but that it is the job of editors, and the policy of the British Journal ofCancer, to encourage properly controlled and designed clinical studies with high ethical standards, adequate patient numbers and careful con-
sideration ofappropriate inclusion of all patients. The inclus-
ion in a paper of unevaluable patients, patients withdrawn
after randomisation or analysis which does not take account
principally ofintention-to-treat, are likely to place a paper at
a substantial disadvantage. Biomedical statisticians are
powerful reviewers of clinical papers in the British Journal of Cancer and probably come nearest to having a veto on the2 EDITORIAL
publication of a paper if there is a consensus among them
that it is methodologically unsound. We still sometimes pub-
lish clinical descriptions and retrospective analyses of large
patient series if they are useful, but we favour carefully-
conducted prospective clinical investigation.
Statistical methodology remains a bone of considerable
contention in clinical papers. Much professional expertise
does exist in the field among clinicians and their colleagues
and few major studies are planned without input from a
full-time professional statistician. However, not all clinical
researchers have access to such people and there is still
disagreement in many quarters about ideal choice ofmethods
and their limitations. There may not be a Great Divide
between statisticians and clinicians, but there is a small one.
Perhaps Journal editors should take a more active role in
establishing consensus and relaying the ground rules in this
area. We are giving consideration to this at the British Jour-
nal of Cancer.
The Clinical Section of the British Journal of Cancer has
grown rapidly in the last 3 years. The number of submitted
manuscripts has increased very substantially and continues to
do so. The acceptance rate is now held constant and pressure
upon the size of the Journal and its consequent cost is
increasing. The peer review process still works with all its
imperfections and we continually try to improve it. We hope
we will continue to receive good clinical manuscripts from all
over the world and to handle them as quickly as possible and
come to accurate and fair judgements regarding acceptance
for publication. In the Clinical Office, as in the Cambridge
Office, we try to arrive at our decisions and issue them whilst
retaining our sense of proportion and sense of humour! We
hope that this series of editorials will help our authors and
readers to understand the process better and to give as much
constructive feedback as they think we can take.
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